Effects of Budesonide and Fluticasone Propionate in Pediatric Asthma Patients
Cytokines and chemokines play important roles in asthma. However, little information exists on the effects of inhaled corticosteroids on cytokine and chemokine plasma levels in childhood asthma. We compared the pharmaceutical effects of two inhaled corticosteroids used in pediatric patients with mil...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2010-02-01
|
Series: | Pediatrics and Neonatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1875957210600071 |
id |
doaj-544e2bbac3b14a0f9db35a03a1563a7e |
---|---|
record_format |
Article |
spelling |
doaj-544e2bbac3b14a0f9db35a03a1563a7e2020-11-24T22:13:53ZengElsevierPediatrics and Neonatology1875-95722010-02-01511313610.1016/S1875-9572(10)60007-1Effects of Budesonide and Fluticasone Propionate in Pediatric Asthma PatientsLin-Yu Kuo0Chih-Hsing Hung1Hsing-I Tseng2Jiunn-Ren Wu3Yuh-Jyh Jong4Yu-Te Chu5Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TaiwanDepartment of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TaiwanDepartment of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TaiwanDepartment of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TaiwanDepartment of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TaiwanDepartment of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, TaiwanCytokines and chemokines play important roles in asthma. However, little information exists on the effects of inhaled corticosteroids on cytokine and chemokine plasma levels in childhood asthma. We compared the pharmaceutical effects of two inhaled corticosteroids used in pediatric patients with mild-to-moderate asthma, budesonide and fluticasone propionate. Methods: Pediatric patients aged 5–18 years old were enrolled in this randomized, open-label, observer-blinded study and received 3 months of treatment with either inhaled budesonide (200 mg/puff) or fluticasone propionate (250 mg/puff), at two puffs per day. Peak expiratory flow (PEF), exhaled nitric oxide, Asthma Control Test (ACT), plasma levels of tumor necrosis factor-a, thymus and activation-regulated chemokine, and interferon-inducible protein 10 were measured before treatment and monthly for 3 months after treatment. Results: There were six patients in the budesonide group, and eight in the fluticasone group. After 3 months, both groups showed improved PEF. In the first month, PEF improved more in the budesonide group than in the fluticasone group, though the difference was not significant. After treatment, ACT scores in both groups were well controlled, except for one patient in the fluticasone group. The fluticasone group had a more significant reduction in exhaled nitric oxide than the budesonide group in the first month. Conclusion: Improvements in lung function were more rapid in the budesonide group than the fluticasone group. However, patients in the fluticasone group had better anti-inflammatory responses than those in the budesonide group. We conclude that each inhaled corticosteroids have its own clinical and laboratory effects.http://www.sciencedirect.com/science/article/pii/S1875957210600071asthmabudesonidechemokinecytokineexhaled NOfluticasone |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lin-Yu Kuo Chih-Hsing Hung Hsing-I Tseng Jiunn-Ren Wu Yuh-Jyh Jong Yu-Te Chu |
spellingShingle |
Lin-Yu Kuo Chih-Hsing Hung Hsing-I Tseng Jiunn-Ren Wu Yuh-Jyh Jong Yu-Te Chu Effects of Budesonide and Fluticasone Propionate in Pediatric Asthma Patients Pediatrics and Neonatology asthma budesonide chemokine cytokine exhaled NO fluticasone |
author_facet |
Lin-Yu Kuo Chih-Hsing Hung Hsing-I Tseng Jiunn-Ren Wu Yuh-Jyh Jong Yu-Te Chu |
author_sort |
Lin-Yu Kuo |
title |
Effects of Budesonide and Fluticasone Propionate in Pediatric Asthma Patients |
title_short |
Effects of Budesonide and Fluticasone Propionate in Pediatric Asthma Patients |
title_full |
Effects of Budesonide and Fluticasone Propionate in Pediatric Asthma Patients |
title_fullStr |
Effects of Budesonide and Fluticasone Propionate in Pediatric Asthma Patients |
title_full_unstemmed |
Effects of Budesonide and Fluticasone Propionate in Pediatric Asthma Patients |
title_sort |
effects of budesonide and fluticasone propionate in pediatric asthma patients |
publisher |
Elsevier |
series |
Pediatrics and Neonatology |
issn |
1875-9572 |
publishDate |
2010-02-01 |
description |
Cytokines and chemokines play important roles in asthma. However, little information exists on the effects of inhaled corticosteroids on cytokine and chemokine plasma levels in childhood asthma. We compared the pharmaceutical effects of two inhaled corticosteroids used in pediatric patients with mild-to-moderate asthma, budesonide and fluticasone propionate.
Methods: Pediatric patients aged 5–18 years old were enrolled in this randomized, open-label, observer-blinded study and received 3 months of treatment with either inhaled budesonide (200 mg/puff) or fluticasone propionate (250 mg/puff), at two puffs per day. Peak expiratory flow (PEF), exhaled nitric oxide, Asthma Control Test (ACT), plasma levels of tumor necrosis factor-a, thymus and activation-regulated chemokine, and interferon-inducible protein 10 were measured before treatment and monthly for 3 months after treatment.
Results: There were six patients in the budesonide group, and eight in the fluticasone group. After 3 months, both groups showed improved PEF. In the first month, PEF improved more in the budesonide group than in the fluticasone group, though the difference was not significant. After treatment, ACT scores in both groups were well controlled, except for one patient in the fluticasone group. The fluticasone group had a more significant reduction in exhaled nitric oxide than the budesonide group in the first month.
Conclusion: Improvements in lung function were more rapid in the budesonide group than the fluticasone group. However, patients in the fluticasone group had better anti-inflammatory responses than those in the budesonide group. We conclude that each inhaled corticosteroids have its own clinical and laboratory effects. |
topic |
asthma budesonide chemokine cytokine exhaled NO fluticasone |
url |
http://www.sciencedirect.com/science/article/pii/S1875957210600071 |
work_keys_str_mv |
AT linyukuo effectsofbudesonideandfluticasonepropionateinpediatricasthmapatients AT chihhsinghung effectsofbudesonideandfluticasonepropionateinpediatricasthmapatients AT hsingitseng effectsofbudesonideandfluticasonepropionateinpediatricasthmapatients AT jiunnrenwu effectsofbudesonideandfluticasonepropionateinpediatricasthmapatients AT yuhjyhjong effectsofbudesonideandfluticasonepropionateinpediatricasthmapatients AT yutechu effectsofbudesonideandfluticasonepropionateinpediatricasthmapatients |
_version_ |
1725799545417236480 |